Littlewood 2001.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 375, breast, Non‐Hodgkin lymphoma, multiple myeloma, Hodgkin disease, chronic lymphocytic leukemia, gastrointestinal, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = 12‐15 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: transfusion; secondary: Hb, Hct, reticulocytes, predictors for response, QoL, after protocol amendment also survival
Notes	study number = 17123
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer‐generated randomization schedule prepared by RWJPRI
Allocation concealment?	Low risk	coded drug packs of identical appearance